Acute Morphine Induces Matrix Metalloproteinase-9 Up-Regulation in Primary Sensory Neurons to Mask Opioid-Induced Analgesia in Mice by Yen-Chin Liu et al.
RESEARCH Open Access
Acute morphine induces matrix
metalloproteinase-9 up-regulation in primary
sensory neurons to mask opioid-induced
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Abstract
Background: Despite decades of intense research efforts, actions of acute opioids are not fully understood.
Increasing evidence suggests that in addition to well-documented antinociceptive effects opioids also produce
paradoxical hyperalgesic and excitatory effects on neurons. However, most studies focus on the pronociceptive
actions of chronic opioid exposure. Matrix metalloproteinase 9 (MMP-9) plays an important role in
neuroinflammation and neuropathic pain development. We examined MMP-9 expression and localization in dorsal
root ganglia (DRGs) after acute morphine treatment and, furthermore, the role of MMP-9 in modulating acute
morphine-induced analgesia and hyperalgesia in mice.
Results: Subcutaneous morphine induced a marked up-regulation of MMP-9 protein in DRGs but not spinal cords.
Morphine also increased MMP-9 activity and mRNA expression in DRGs. MMP-9 up-regulation peaked at 2 h but
returned to the baseline after 24 h. In DRG tissue sections, MMP-9 is expressed in small and medium-sized neurons
that co-express mu opioid receptors (MOR). In DRG cultures, MOR agonists morphine, DAMGO, and remifentanil
each increased MMP-9 expression in neurons, whereas the opioid receptor antagonist naloxone and the MOR-
selective antagonist D-Phe-Cys-Tyr-D-Trp-Arg-Thr-Pen-Thr-NH2 (CTAP) suppressed morphine-induced MMP-9
expression. Notably, subcutaneous morphine-induced analgesia was enhanced and prolonged in Mmp9 knockout
mice and also potentiated in wild-type mice receiving intrathecal injection of MMP-9 inhibitors. Consistently,
intrathecal injection of specific siRNA targeting MMP-9 reduced MMP-9 expression in DRGs and enhanced and
prolonged morphine analgesia. Subcutaneous morphine also produced heat hyperalgesia at 24 h, but this opioid-
induced hyperalgesia was not enhanced after MMP-9 deletion or inhibition.
Conclusions: Transient MMP-9 up-regulation in DRG neurons can mask opioid analgesia, without modulating
opioid-induced hyperalgesia. Distinct molecular mechanisms (MMP-9 dependent and independent) control acute
opioid-induced pronociceptive actions (anti-analgesia in the first several hours and hyperalgesia after 24 h).
Targeting MMP-9 may improve acute opioid analgesia.
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Background
Opioids especially mu opioid receptor (MOR) agonists
remain to be the most effective treatment for moderate
to severe pain. MOR is expressed by primary sensory
neurons including small-sized (C-fiber) and medium-
sized (Aδ-fiber) neurons in the dorsal root ganglia
(DRGs) [1-5]. MOR is also expressed in primary afferent
terminals and lamina II interneurons in the spinal cord
[1,6-8]. MOR agonist, such as [D-Ala2, N-Me-Phe4,
Gly5-ol]-enkephalin (DAMGO) elicits potent presynap-
tic inhibition via suppressing N-type Ca2+ channels and
neutrotransmitter release in the superficial dorsal horn
[9-12]. Postsynaptically, MOR agonists open G protein-
coupled inwardly rectifying potassium (GIRK) channels
and induce membrane hyperpolarization of dorsal horn
neurons [12,13]. In addition, opioid produced by
immune cells can also elicit peripheral analgesia by acti-
vating opioid receptors on nerve terminals [14,15].
Accumulating evidence from animal and human stu-
dies suggests that opioids also produce paradoxical exci-
tatory and hyperalgesic effects. This phenomenon is
known as opioid-induced hyperalgesia (OIH), as a result
of up-regulation of pronociceptive pathways in the cen-
tral and peripheral nervous systems [16-18]. A brief
exposure to fentanyl or morphine induces long-lasting
hyperalgesia [19,20]. An early study by Chen and Huang
demonstrated that MOR agonist caused a sustained
potentiation of NMDA receptor-mediated glutamate
responses in spinal trigeminal neurons [21]. Recently,
Drdla et al. (2009) reported that abrupt withdrawal from
DAMGO induced long-term potentiation (LTP) in the
spinal cord via NMDA receptor-mediated postsynaptic
mechanisms [22,23]. Moreover, Zhou et al. (2010)
demonstrated that DAMGO-induced LTP required pre-
synaptic mechanisms and TRPV1-expressing primary
afferents in the spinal cord [24].
Matrix metalloproteases (MMPs) consist of a large
family of endopeptidases that require Zn2+ for their
enzyme activity and play a critical role in inflammation
through the cleavage of the extracellular matrix proteins,
cytokines, and chemokines [25-27]. The gelatinases
MMP-9 and MMP-2 are two of the best-studied MMP
family members. The activity of MMP-9 is regulated by
endogenous inhibitors, especially TIMP-1 (tissue inhibi-
tor of metalloprotease-1) [28]. MMP-9 is involved in a
wide range of CNS diseases including Alzheimer’s,
amyotrophic lateral sclerosis, multiple sclerosis, brain
and spinal cord trauma, epilepsy, and stroke [29]. By
degrading extracellular matrix, MMP-9 damages the
blood-brain barrier, resulting in edema and vascular
leakage in the CNS. Recently, we have demonstrated
distinct roles of MMP-9 and MMP-2 in neuropathic
pain development: (i) transient MMP-9 up-regulation
after nerve injury is critical for the early-phase develop-
ment of neuropathic pain; (ii) sustained MMP-2 up-reg-
ulation maintains neuropathic pain; and (iii) MMP-9
and MMP-2 induce the active cleavage of IL-1b (activa-
tion) in early and late-phase of nerve injury, respectively
[28,30]. MMP-9 up-regulation in the spinal cord has
also been implicated in chronic opioid-induced withdra-
wal syndrome (morphine dependence) through possible
neuronal activation and interaction with NMDA recep-
tors (NR1 and NR2B) via integrin-beta1 and NO path-
ways [31]. It is unclear whether MMP-9 also plays a role
in acute opioid-induced pronociceptive responses. Our
data demonstrated that acute morphine treatment via
either subcutaneous or intrathecal route induced rapid
and transient MMP-9 up-regulation (1-3 h) in primary
sensory neurons to counteract opioid analgesia in the
first several hours. In contrast, OIH at 24 h was not
affected by MMP-9 deletion or inhibition.
Results
Subcutaneous morphine treatment increases MMP-9
expression and activity in DRGs
As a first step to define the role of MMP-9 in opioid
analgesia, we conducted a time course study to examine
MMP-9 protein and activity levels in lumbar DRGs
using Western blot and zymography, respectively. Wes-
tern blotting revealed that MMP-9 began to increase at
1 h, peaked at 2 h (4.3 fold of control, P < 0.05, n = 4),
and declined at 3 h (2.4 fold of control, P < 0.05, n = 4)
(Figure 1A). Gelatin zymography showed a parallel
increase of MMP-9 activity in the DRG at 1 h (1.71 fold
of control, P < 0.05, n = 4) and 2 h (2.0 fold of control;
P < 0.05, n = 4) (Figure 1B). Therefore, both the protein
and activity levels of MMP-9 are increased in DRGs
after morphine injection, peaking at 2 h. Notably, the
activity of another gelatinase, MMP-2, a close family
member of MMP-9, did not change after subcutaneous
morphine (Figure 1B, P > 0.05, n = 4), suggesting a
unique role of MMP-9 in response to acute opioid.
We also examined MMP-9 expression in the lumbar
spinal cord of morphine-treated mice. In sharp contrast,
we did not find significant changes in MMP-9 protein
expression in the spinal cord dorsal horn at all the
times we tested after morphine injection (Figure 1C, P >
0.05, n = 4). Neither did we observe MMP-9 activity
change in the dorsal horn 2 h after the morphine treat-
ment (Additional file 1).
To determine whether MMP-9 up-regulation is caused
by transcriptional regulation, we also performed quanti-
tative RT-PCR to determine MMP-9 and TIMP-1
mRNA levels, in DRGs at different times following acute
morphine treatment. Morphine elicited a significant
increase in MMP-9 mRNA expression at 2 h (2.3 fold of
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control, P < 0.05, n = 4, Figure 2A) but a delayed
increase in TIMP-1 mRNA expression at 3 h (3.2 fold of
control, P < 0.05, n = 4, Figure 2B). Up-regulation of
TIMP-1, the endogenous inhibitor of MMP-9, is likely
to suppress MMP-9 expression to control its detrimen-
tal actions. By contrast, morphine did not alter MMP-9
mRNA expression in the spinal cord dorsal horn at all
the times we tested (Additional file 1).
In situ hybridization confirmed a significant increase
of MMP-9 mRNA levels in lumbar DRGs 2 h after mor-
phine injection (P < 0.05, n = 4, Figure 2C-F). MMP-9
mRNA expression was only observed in DRG neurons
(Figure 2C-E). Interestingly, after morphine treatment,
strong mRNA signals were found in subcellular regions
close to the surface of DRG neurons (Figure 2D, E).
Subcutaneous morphine induces MMP-9 in MOR-
expressing DRG neurons
Immunohistochemistry showed that MMP-9 was
expressed in 24.2 ± 3.9% DRG neurons in saline-treated
mice, and this percentage was significantly increased 2 h
after morphine treatment (P < 0.05, n = 4, Figure 3A-C),
in support of the Western blot results. MMP-9 immunor-
eactivity was abolished in Mmp9 knockout mice or after
omitting the primary antibody (Additional file 1). Of note,
MOR expression per se did not change at 2 h after mor-
phine injection (Figure 3A, B, and 3D). Double staining
indicated that the percentage of DRG neurons expressing
both MMP-9 and MOR increased from 18.9 ± 3.9% in
vehicle-treated animals to 31.7 ± 3.6% in morphine-treated
animals (1.7 fold of control, P < 0.05, n = 4) (Figure 3E).
Further characterization demonstrated that MMP-9 was
largely colocalized with MOR and more than 70% MMP-
9-positive neurons expressed MOR in morphine-treated
animals (Figure 3F). In particular, MOR-expressing neu-
rons showed a significant increase in MMP-9 expression
after morphine treatment: the percentage of MOR-positive
neurons expressing MMP-9 increased from 42.9 ± 10.1%
in vehicle-treated group to 74.2 ± 6.0% in morphine-trea-
ted group (P < 0.05, n = 4) (Figure 3F). Size frequency ana-
lysis revealed that majority of MMP-9 and MOR-positive
cells were distributed in small- and medium-sized neu-
rons; with mean cross sectional areas of 510 ± 283 μm2
Figure 1 Subcutaneous morphine increases MMP-9 expression
and activity in DRGs. (A) Western blotting showing the time
course of MMP-9 expression in lumbar DRGs after morphine (s.c., 10
mg/kg). (B) Gelatin zymography showing the time course of MMP-9
activity in lumbar DRGs after morphine. Note that MMP-2 activity
remains unchanged after morphine injection. (C) Western blotting
showing the time course of MMP-9 expression in lumbar spinal
cord dorsal horns after morphine (s.c., 10 mg/kg). Note that
subcutaneous morphine only induces MMP-9 expression in DRGs
but not spinal cords. *P < 0.05, compared to naive control, ANOVA
followed by Bonferroni post hoc test, n = 4 mice.
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and 407 ± 221 μm2, respectively (Figure 4A, B). No signifi-
cant size shift of the MMP-9 or MOR positive-neurons
was detected after morphine treatment (Figure 4A, B).
MOR agonists increase MMP-9 expression in dissociated
DRG neurons
How does morphine induce MMP-9 expression? Subcuta-
neous morphine could induce MMP-9 expression in DRG
neurons via opioid receptor-independent mechanisms,
such as toll-like receptor-mediated activation of glial cells,
leading to release of glial mediators to interact with neu-
rons [32,33]. To exclude this possibility, we investigated
whether morphine would induce MMP-9 expression
through a direct activation of MOR in cultured DRG neu-
rons. As in DRG sections, MMP-9 was also expressed by
neurons (NeuN+) in DRG cultures (Figure 5A). Incubation
of dissociated DRG neurons with morphine (1 and 10 μM,
2 h) elicited a dose-dependent increase in MMP-9 levels
(Figure 5B, C). This increase was not significant (P > 0.05,
n = 4 cultures) after 1 μM morphine treatment (Figure
5C). However, the intensity of MMP-9 immunoreactivity
in DRG cultures significantly increased after 10 μM mor-
phine treatment (2.6 fold of control, P < 0.05, n = 4 cul-
tures, Figure 5C). Since 50 μM morphine did not further
increase MMP-9 levels, compared to 10 μM morphine
(Figure 5C), we used 10 μM morphine for the remaining
Figure 2 Subcutaneous morphine induces MMP-9 and TIMP-1 mRNA up-regulation in DRGs. (A, B) RT-PCR showing time course of
subcutaneous morphine-induced MMP-9 (A) and TIMP-1 (B) mRNA expression in DRGs. *P < 0.05, compared to naive control, ANOVA followed
by Bonferroni post hoc test, n = 4 mice. (C-E) In situ hybridization showing MMP-9 mRNA expression in DRG neurons 2 h after subcutaneous
injection of saline (A) and morphine (B, C). Scale, 50 μm. The box in D is enlarged in E. Note strong MMP-9 mRNA staining (arrows) near cell
surface following morphine treatment. (F) Percentage of MMP-9 mRNA-positive neurons in DRGs. *P < 0.05, compared to vehicle (saline),
Student’s t-test, n = 4 mice.
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study. Notably, morphine-evoked MMP-9 increase was
found in a ring next to membrane (Figure 5B), indicating a
readiness for release of this protease in response to cellular
stress. This increase was suppressed by naloxone (10 and
50 μM, P < 0.05, n = 4), a general opioid receptor antago-
nist, and also by D-Phe-Cys-Tyr-D-Trp-Arg-Thr-Pen-
Thr-NH2 (CTAP, 50 μM, P < 0.05, n = 4, Figure 5C), a
specific MOR antagonist. In parallel, incubation of DRG
cultures with specific MOR agonist DAMGO (1 and 10
μM, 2 h) and remifentanil (1 and 10 μM, 2 h), a short act-
ing MOR agonist [34], also evoked dose-dependent
increases in MMP-9 expression (P < 0.05, n = 4, Figure
5C). Collectively, our findings support a direct action of
opioids on DRG neurons to induce MMP-9 expression,
via specific activation of MOR.
MMP-9 masks opioid analgesia induced by subcutaneous
morphine and DAMGO
To assess the role of MMP-9 in acute morphine
analgesia, we tested morphine analgesia in knockout
(KO) mice lacking Mmp9 (Mmp9 -/-) and the same
FVB genetic background wild-type (WT) control mice.
We did not find difference in the baseline tail flick
withdrawal latency between KO and WT mice (Figure
6A, P > 0.05, n = 7-8 mice). Subcutaneous injection of
morphine (10 mg/kg) induced a transient analgesia in
WT mice, peaking at 0.5 and 1 h and declining at 2 h.
Interestingly, Mmp9-KO mice exhibited enhanced
morphine analgesia at 2 h (Figure 6A, P < 0.05, n = 7
mice).
Since Mmp9-KO mice are not conditional (see Meth-
ods), MMP-9 could regulate opioid analgesia at different
sites/levels of the nervous system (e.g., DRG, spinal
cord, and supraspinal). To focus on DRG and spinal
cord levels, we delivered MMP-9 inhibitors [30], via
intrathecal route, to target MMP-9 in the DRG and
spinal cord [30]. Intrathecal injection of TIMP-1 (0.1
μg), an endogenous inhibitor of MMP-9 [30], signifi-
cantly potentiated morphine analgesia at 2 h (Figure 6B,
P < 0.05, n = 7 mice). Intrathecal injection of MMP-9
inhibitor-I (0.2 μg), a small molecule inhibitor of MMP-
9 [30], not only potentiated morphine analgesia at 2 h
Figure 3 Subcutaneous morphine-induced MMP-9 increase is enriched in mu opioid receptor (MOR)-expressing DRG neurons. (A, B)
Double staining showing colocalization of MMP-9 and MOR in DRG neurons of saline (A) and morphine (B) treated mice (s.c., 10 mg/kg). Scale,
50 μm. (C, D) Percentage of MMP-9+ (C) and MOR + (D) neurons in DRGs 2 h after saline and morphine injection. (E) Percentage of MMP-9 and
MOR double-positive neurons in DRGs 2 h after saline and morphine injection. (F) Percentage of MMP-9-positive neurons expressing MOR and
percentage of MOR-positive neurons expressing MMP-9 in DRGs 2 h after saline and morphine injection. S, saline; M, morphine. *P < 0.05,
compared to saline, Student’s t-test, n = 4 mice.
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but also prolonged morphine analgesia for > 3 h (Figure
6C, P < 0.05, n = 8- 10 mice).
Next, we investigated the role of MMP-9 in opioid
analgesia induced by a selective MOR agonist, DAMGO.
Subcutaneous injection of DAMGO (10 mg/kg) induced
analgesia for > 2 h, and this analgesia was potentiated
and prolonged by MMP-9 inhibitor-I (i.t., 0.2 μg, Figure
6D, P < 0.05, n = 9 mice).
Since the dose of 10 mg/kg of morphine induced a
ceiling effect in the tail-flick test (near cut-off value at
0.5 and 1 h), reducing the ability to demonstrate an
actual enhancement of morphine-induced analgesia in
early times, we also tested morphine analgesia at a
lower dose (5 mg/kg) in WT and Mmp9-KO mice. Of
note, morphine analgesia following the lower dose was
also significantly potentiated in Mmp9-KO mice (Figure
6E, P < 0.05, n = 5 mice).
We further evaluated the role of MMP-9 in opioid
analgesia using siRNA strategy to knockdown MMP-9
expression in the DRG/spinal cord via intrathecal route
[25,35]. Our previous study showed that intrathecal
injections of MMP-9 siRNA specifically reduced MMP-9
but not MMP-2 activity in DRGs after nerve injury [30].
The same siRNA treatment (3 μg, i.t., given 24 and 2 h
before s.c. morphine injection) also reduced MMP-9
expression in the DRG (Figure 7A, B, P < 0.05, n = 5
mice) but not in the spinal cord (Figure 7C, D, P > 0.05,
n = 5 mice). One possible explanation for the differen-
tial knockdown of DRG vs. spinal cord MMP-9 by
intrathecal siRNA treatment is that in the context of
our experimental condition the inducible MMP-9
expression in DRGs is more sensitive to siRNA treat-
ment than the constitutive MMP-9 expression in spinal
cords, as shown in our previous study [25,30]. Impor-
tantly, the MMP-9 siRNA treatment also enhanced mor-
phine analgesia (10 mg/kg) at 2 h (Figure 7E, P < 0.05, n
= 5 mice). Since the siRNA treatment only reduced
MMP-9 levels in DRGs but not in spinal cords, MMP-9
expressed by DRG cells should play an important role in
mediating pronociceptive actions of opioid.
Intrathecal morphine and remifentanil induce MMP-9
expression in DRGs
Our data showed that subcutaneous morphine elicited
MMP-9 expression in the DRG but not in the spinal
cord (Figure 1). This failure of systemic morphine to
induce MMP-9 expression in the spinal cord may result
from limited access of morphine to the spinal cord (part
of the central nervous system) following systemic injec-
tion. To determine whether acute delivery of MOR ago-
nists to the spinal cord would induce MMP-9
expression in the spinal cord, we administrated mor-
phine and remifentanil intrathecally via lumbar puncture
and collected DRG and spinal cord dorsal horn tissues 2
h later. Intrathecal morphine (10 nmol) and remifentanil
(1 noml) elicited significant MMP-9 expression in DRGs
(Figure 8A, B; 1.8 fold and 2.3 fold of control, respec-
tively, P < 0.05, n = 4 mice). In contrast, intrathecal
morphine and remifentanil failed to induce MMP-9
expression in the spinal cord dorsal horn (Figure 8C, D;
P > 0.05, n = 4 mice). These results further suggest that
DRG is a primary site for acute opioid-induced MMP-9
expression.
We also examined the correlation between intrathecal
morphine-induced MMP-9 expression and intrathecal
morphine-induced analgesia. Intrathecal morphine (10
Figure 4 Actue morphine treatment does not change the sizes
of MMP-9- and MOR-positive neurons in DRGs. (A, B) Size
frequency distribution (percentage) of MMP-9-positive neurons (A)
and MOR-positive neurons (B) in DRGs 2 h after subcutaneous saline
and morphine. 300-500 neurons from 3 animals were plotted in
each group. Note that MMP-9 and MOR are mainly expressed in
small- and medium-sized neurons.
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nmol) induced robust analgesia in WT mice, which
lasted > 2 h and recovered after 3 h (Figure 8E). Com-
pared to WT mice, Mmp9-KO mice displayed enhanced
analgesia at 2 h and prolonged analgesia for > 3 h (Fig-
ure 8E; P < 0.05, n = 7 mice).
MMP-9 does not regulate morphine-induced hyperalgesia
Finally, we tested if morphine could induce MMP-9
expression in a late-time point (24 h) and its relevance to
OIH. Subcutaneous morphine only induced a transient
MMP-9 expression in the first 3 h (Figure 1) but not after
Figure 5 MOR agonists increase MMP-9 expression in dissociated neurons of DRG cultures. (A) Triple staining of MMP-9, NeuN (neuronal
marker), and DAPI (nuclei marker for all cells). Note that MMP-9 is only expressed in neurons (arrows). Scale, 100 μm. (B) Double staining
showing MMP-9 and NeuN expression in dissociated DRG neurons in control cultures and cultures treated with morphine (10 μM, 2 h). Left
panels show all neurons (NeuN+) in the field. Right panels show high magnification images of middle panels. Scales, 100 μm (middle) and 25
μm (right). (C) Intensity of MMP-9-positive neurons in DRG cultures after treatment of morphine (1, 10, and 50 μM, 2 h), DAMGO and
remifentanil (1 and 10 μM, 2 h), together with the opioid receptor antagonist naloxone and MOR antagonist CTAT (10 and 50 μM). Note that
morphine-induced MMP-9 increase is inhibited by naloxone and CTAP. *P < 0.05, compared to control; #P < 0.05, ANOVA followed by Bonferroni
post hoc test. The data were also analyzed by non-parametric Kruskal-Wallis test followed by Mann-Whitney test. n = 4 cultures.
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24 h (Figure 9A, B, P > 0.05, n = 4 mice). In order to
unmask OIH, we tested tail flick latency at 48°C instead of
52°C, at 24 h after morphine injection, according to the
protocol of Elhabazi et al. [15]. Subcutaneous morphine
induced a significant heat hyperalgesia at 24 h in WT
mice (Figure 9C, P < 0.05, n = 5 mice). Notably, OIH is
comparable in WT and Mmp9-KO mice (Figure 9C, P >
0.05, n = 5 mice). In parallel, intrathecal pre-treatment of
MMP-9 inhibitor-I also failed to prevent OIH at 24 h (Fig-
ure 9D, P > 0.05, n = 5 mice). Thus, MMP-9 is only
involved in masking opioid-induced analgesia in the first
several hours but not participated in OIH after 24 h.
Figure 6 MMP-9 deficiency or inhibition causes enhanced opioid analgesia after subcutaneous injection of morphine and DAMGO. (A)
Morphine (10 mg/kg, s.c) analgesia, as measured by tail flick latency, in wild-type and Mmp9-KO mice. *P < 0.05, compared to wild-type control,
Student’s t-test, n = 7. (B, C) Morphine (10 mg/kg, s.c) analgesia in wild-type mice after intrathecal injection of TIMP-1 (0.2 μg, B) and MMP-9
inhibitor-I (0.2 μg, C). *P < 0.05, compared to vehicle (10% DMSO or saline), Student’s t-test, n = 7-10 mice. (D) DAMGO (10 mg/kg, s.c) analgesia
in wild-type mice after intrathecal injection of MMP-9 inhibitor-I (0.2 μg) or vehicle (10% DMSO). *P < 0.05, compared to vehicle, Student’s t-test,
n = 9 mice. (E) Analgesia induced by low dose morphine (5 mg/kg, s.c) in wild-type and Mmp9-KO mice. *P < 0.05, compared to Wild-type
control. Student’s t-test, n = 5 mice. BL, baseline. Note that opioid analgesia by subcutaneous morphine or DAMGO is potentiated and
prolonged in Mmp9-KOmice and after pharmacological inhibition of MMP-9.
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Discussion
Our data demonstrated that acute morphine treatment
induced rapid MMP-9 up-regulation in primary sensory
neurons to counteract opioid-induced analgesia but had
no role in promoting OIH. First, subcutaneous and
intrathecal morphine induced a rapid and transient (< 3
h) MMP-9 up-regulation in DRG neurons but not in
the spinal cord. Second, MOR agonists morphine,
DAMGO, and remifentanil increased MMP-9 expression
in dissociated DRG neurons, in a MOR-dependent man-
ner. Third, Mmp9 deletion or inhibition (via intrathecal
route) enhanced and prolonged opioid analgesia in the
first several hours but did not impact OIH after 24 h.
To our knowledge, this is the first time to demonstrate
that different molecular mechanisms control different
pronociceptive actions of opioids: opioid-induced anti-
analgesia during acute opioid analgesia (first 3 h) vs.
OIH after opioid withdrawal (> 24 h).
Several lines of evidence from preclinical and clinical
studies suggest that opioids may produce paradoxical
hyperalgesia [17]. OIH is thought to result from the up-
regulation of pronociceptive pathways within the central
and peripheral nervous systems [18,16]. Traditionally,
OIH has been associated with chronic pain and analge-
sic tolerance to opioids after long-term exposure to
opioids. It is well documented that chronic opioid
induces the expression of pronociceptive genes in DRGs
(e.g., TRPV1, substance P, CGRP, chemokine) [26,27,36]
and spinal cords (e.g., prodynorphin, NK-1, and PKCg)
[37-39], promoting opioid-induced antinociceptive toler-
ance and hyperalgesia. Sustained morphine exposure
also induces MMP-9 up-regulation in the spinal cord,
leading to opioid-induced withdrawal responses that
might be associated with morphine dependence [31].
Furthermore, recent studies suggest that acute OIH can
occur after intraoperative or postoperative administra-
tion of high doses of potent opioids, leading to increased
postoperative pain [17,40]. For example, enhancement of
experimentally induced hyperalgesia was observed in
humans after infusion of remifentanil, a short-acting
potent opioid, in several volunteer studies [40]. In
rodents, acute fentanyl not only produces potent analge-
sia but also elicits secondary long-lasting hyperalgesia
for several days [19]. A single dose of intrathecal mor-
phine induces long-lasting hyperalgesia in rats [20].
Activation of spinal cord NMDA receptors has been
strongly implicated in the development of OIH, since
the use of clinically available NMDA receptor antago-
nists such as ketamine and dextromethorphan can
attenuate OIH [17,20,40]. Recently, Drdla et al. (2009)
Figure 7 Intrathecal administration of MMP-9 siRNA reduces
MMP-9 expression in DRGs and enhances morphine analgesia.
(A-D) Western blotting showing MMP-9 expression in DRGs (A, B)
and spinal cord dorsal horns (C, D) after intrathecal injections of
MMP-9 siRNA or control siRNA (3 μg, 24 and 2 h before the s.c.
morphine injection. B and D are quantification of the MMP-9 bands
in DRGs (B) and spinal cords (D). *P < 0.05, compared to control
(CTRL); Mann-Whitney test, n = 4 mice. (E) Enhanced morphine
analgesia after intrathecal treatment of MMP-9 siRNA. *P < 0.05,
compared to control siRNA, Student’s t-test, n = 5 mice. BL,
baseline.
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Figure 8 Up-regulation of MMP-9 expression in DRGs but not spinal cords after intrathecal morphine or remifentanil and potentiation
of intrathecal morphine analgesia in Mmp9 deficient mice. (A-D) Western blotting showing MMP-9 expression in DRGs (A, B) and spinal
cord dorsal horns (C, D) 2 h after intrathecal injection of morphine (10 nmol) or remifentanil (1 nmol). B and D are quantification of the MMP-9
bands in DRGs (B) and spinal cords (D). *P < 0.05, compared to control, ANOVA followed by Bonferroni post hoc test, n = 4 mice. CTRL, control;
MORPH, morphine; REMIF, remifentanil. (E) Mmp9-KO mice exhibit enhanced and prolonged analgesia after intrathecal morphine (10 nmol). *P <
0.05, compared to Wild-type control, Student’s t-test, n = 7 mice. BL, baseline.
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have shown that abrupt opioid withdrawal induces LTP
in spinal cord dorsal horn neurons via activation of
opioid receptors and NMDA receptors, providing a cel-
lular mechanism of OIH [22]. Zhou et al. (2010) have
further demonstrated that DAMGO-induced spinal LTP
requires TRPV1-expressing primary afferents, suggesting
an involvement of presynaptic mechanisms [24]. Despite
the progress in revealing mechanisms of OIH, it is still
unclear whether acute opioid can induce gene expres-
sion in primary sensory neurons to mediate the pronoci-
ceptive actions of opioid.
We demonstrated a novel role of MMP-9 in masking
opioid analgesia. First, morphine analgesia induced by
both subcutaneous and intrathecal morphine was poten-
tiated and prolonged in Mmp9-KO mice. Second,
intrathecal injection of two different MMP-9 inhibitors,
MMP-9 inhibitor-1, a small molecule inhibitor, and
TIMP-1, a peptide inhibitor, potentiated and prolonged
analgesia by subcutaneous morphine and DAMGO
analgesia (Figure 6). Increasing evidence demonstrates
that intrathecal route can target both DRG and spinal
cord cells. Agents with different chemical properties
have been shown to affect DRG cells via intrathecal
route, including small molecules such as MAP kinase
and MMP-9 inhibitors [30,41] and large molecules such
as growth factors and peptides [42,43], as well as anti-
sense oligodeoxynucleotides [44,45] and siRNAs [25,46].
Intrathecal p38 inhibitor rapidly (< 30 min) inhibited
p38 activation in DRG neurons [47]. Intrathecal MMP-9
also causes IL-1b cleavage in the DRG [30]. Notably,
intrathecal morphine and remifentanil induced robust
MMP-9 upregulation in DRG (Figure 8).
In parallel with a role of MMP-9 in masking acute
opioid analgesia, we found MMP-9 up-regulation in
Figure 9 MMP-9 deficiency does not alter opioid-induced hyperalgesia after subcutaneous morphine. (A, B) Western blot gel (A) and
band density (B) showing MMP-9 expression in lumbar DRGs 24 h after morphine (MORPH) injection. *P > 0.05, compared to naive control
(CTRL), Student’s t-test, n = 4 mice. (C, D) Subcutaneous morphine (5 mg/kg) induces comparable heat hyperalgesia in both wild-type and
Mmp9-KO mice (C) and also in wild-type mice pretreated with intrathecal MMP-9 inhibitor-I (0.2 μg) or vehicle (10% DMSO). *P < 0.05, compared
to corresponding baseline (BL), Student’s t-test, n.s., no significance. n = 5 mice. Morphine-induced heat hyperalgesia was tested by tail flick
latency in 48°C hot water.
Liu et al. Molecular Pain 2012, 8:19
http://www.molecularpain.com/content/8/1/19
Page 11 of 17
DRGs but not spinal cords after subcutaneous morphine
(Figure 1) and intrathecal morphine or remifentanil (Fig-
ure 8), suggesting that MMP-9-evoked pronociceptive
actions after acute opioid are likely to be mediated by
MMP-9 from DRG. Gelatin zymography data further
indicated a correlated increase in MMP-9 activity in
DRG following acute morphine. However, we did not
observe any increase in MMP-2 activity after acute mor-
phine, in support of our previous report that MMP-2 is
not involved in early-phase development of neuropathic
pain [30]. We also found a corresponding increase in
MMP-9 mRNA levels in DRG neurons following acute
morphine treatment (Figure 2), suggesting a possible
transcription regulation of MMP-9. However, the
increases of morphine-induced MMP-9 protein and
activity occurred prior to the MMP-9 mRNA increase
(Figures 1 and 2), suggesting possible translational regu-
lation (protein increase in the absence of mRNA
increase) and post-translational regulation (increase in
MMP-9 activity in the absence of protein synthesis), in
addition to transcriptional regulation. Of note, we found
strong mRNA signals in subcellular regions close to the
surface of DRG neurons (Figure 2D, E). Recent evidence
also demonstrated translocation of RNA granules in liv-
ing neurons [48] and RNA translocation was found in
DRG neurons in chronic pain [49]. Consistently, strong
MMP-9 immunoreactivity was found in a ring close to
the surface of cultured DRG neurons (Figure 5B).
Although the finding of morphine-induced MMP-9
mRNA trafficking is interesting, the functional signifi-
cance of the mRNA translocation remains to be
investigated.
Our data indicated that activation of MOR was
required for morphine-induced MMP-9 expression in
DRG neurons. (i) MMP-9 increase was enriched in
MOR-positive neurons following subcutaneous mor-
phine (Figure 3). (ii) Morphine-induced MMP-9 expres-
sion in dissociated DRG neurons was suppressed by
naloxone and the selective MOR antagonist CTAP (Fig-
ure 5C). (iii) MOR agonists DAMGO and remifentanil
increased MMP-9 expression in dissociated neurons
(Figure 5C). The signaling mechanisms underlying
opioid-induced MMP-9 up-regulation in primary sen-
sory neurons are still elusive. Activation of MAP kinase
pathways has been implicated in chronic morphine-
induced gene expression in DRG neurons [50,51]. It is
of interest to test whether MAP kinase pathways are
also involved in acute morphine-induced MMP-9
expression. Although our results support a MOR-depen-
dent mechanism of MMP-9 induction, morphine may
also induce gene expression via MOR-independent
mechanisms. Intrathecal injection of morphine-3-glucur-
onide, a major morphine metabolite, has been shown to
enhance pain via toll-like receptor 4 (TLR4) [32].
Our data also suggested that MMP-9 at DRG level
plays a major role in sabotaging opioid analgesia,
because (i) subcutaneous and intrathecal MOR agonists
induced MMP-9 at the DRG but not spinal cord level
and (ii) intrathecal MMP-9 inhibitors and siRNA poten-
tiated and prolonged opioid analgesia. In particular, low-
dose morphine-induced analgesia was even potentiated
in the acute phase (0.5 and 1 h) in Mmp9-KO mice
(Figure 6E). How can MMP-9 up-regulation in DRG
neurons by morphine induce pronociceptive actions?
Our previous study showed that MMP-9 could be
released in DRG cultures in an activity-dependent man-
ner [30], which may cause active cleavage of IL-1b [28].
IL-1b is activated via cleavage from its precursor by cas-
pase-1 (the IL-1b converting enzyme), as well as by
other enzymes such as trypsin, elastase, collagenase, and
cathepsin G, MMP-9, and MMP-2 [29,52,53]. IL-1b acti-
vation in DRGs is increased after intrathecal MMP-9
treatment [31]. Further, MMP-9-induced pain hypersen-
sitivity is abrogated by IL-1b blockade, suggesting that
IL-1b activation is a downstream mechanism underlying
MMP-9-induced pronociceptive actions [30]. In DRGs,
IL-1b is expressed by satellite glial cells [30,54,55] and
neurons [30,56]. DRG neurons and nociceptors also
express IL-1 receptors [57]. Accumulating evidence sug-
gests that IL-1b causes hyperexcitability of sensory neu-
rons by increasing sodium currents and suppressing
potassium currents [55,57,58]. Intrathecal administration
of interleukin-1 receptor antagonist can potentiate both
intrathecal and systemic morphine-induced analgesia
[59,60]. In a recent study, we have demonstrated that
MMP-9 is required for acute morphine-induced activa-
tion of IL-1b and satellite glial cells in DRGs via neu-
ron-glial interactions [61].
Thus, it is conceivable that MMP-9 might antagonize
morphine analgesia via IL-1b signaling, although we
should not exclude the possibility that MMP-9 may reg-
ulate morphine analgesia via cleavage of other signaling
molecules such as TNF-a and chemokines [28].
In summary, opioids are still the most effective analge-
sics for the treatment of moderate to severe pain. Apart
from well-known inhibitory effects of acute opioids,
acute opioids also elicit paradoxical excitatory and pro-
nociceptive actions in the spinal cord via presynaptic
[24] and postsynaptic [21,22] mechanisms. We further
postulate that opioid-induced excitatory and pronocicep-
tive effects are sequential: (1) anti-analgesic effect during
acute opioid analgesia (first 3 h), (2) hyperalgesic effect
after opioid withdrawal (after 24 h), and (3) antinocicep-
tive tolerance (after several days). We also postulate that
these pronociceptive effects of opioids could be
mediated by distinct mechanisms. Our data suggest that
acute opioid treatment, via either subcutaneous or
intrathecal route, can elicit transient MMP-9 induction
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in primary sensory neurons to antagonize/mask acute
morphine analgesia in the first several hours. However,
MMP-9 is not involved in OIH after 24 h. Thus, target-
ing MMP-9 may enhance and prolong opioid analgesia
in pain conditions such as acute postoperative pain.
Methods
Animals
All experiments were performed in accordance with the
guidelines of the National Institutes of Health and the
International Association for the Study of Pain. All ani-
mals were used under Harvard Medical School Animal
Care institutional guidelines. Adult male mice (25-35 g)
were used for behavioral and biochemical studies. These
mice included CD1 mice (Charles River Laboratories),
Mmp9 knockout (Mmp9-/-) mice with FVB background,
and FVB control wild-type mice. Mmp9 knockout mice
and FVB wild-type mice were obtained from Jackson
Laboratories and bred at Thorn Research Building Ani-
mal Facility of Harvard Medical School. As described on
the website of Jackson laboratories, a targeting vector
containing a neomycin resistance gene driven by the
mouse phosphoglycerate kinase promoter was used to
disrupt most of exon 1 and all of intron 2 of the Mmp9
gene. The construct was electroporated into 129S-
derived ZW4 embryonic stem (ES) cells. Correctly tar-
geted ES cells were injected into C57BL/6 J blastocysts.
The mice were maintained in FVB background for more
than 5 generations. Mice that are homozygous null for
the Mmp9 gene were used in this study. They are viable
and fertile and do not show difference in overall weight
and behavior compared with wild-type mice [30]. Ani-
mals were housed in a 12 h light/dark room with access
to food and water ad libitum.
Drugs and administration
We purchased morphine sulphate and remifentanil from
Hospira Inc, MMP-9 inhibitor-I from Calbiochem (Cata-
logue # 444278), D-Ala(2), N-Me-Phe(4), Gly-ol(5))-
enkephalin (DAMGO), naloxone, and CTAP (D-Phe-
Cys-Tyr-D-Trp-Arg-Thr-Pen-Thr-NH2) from Sigma,
and tissue inhibitor of MMP-I (TIMP-1) from R & D.
Morphine, DAMGO, and remifentanil were freshly pre-
pared in saline and administered subcutaneously [5 or
10 mg/kg for morphine and DAMGO, or intrathecally
(10 nmol for morphine and 1 nmol for remifentanil)].
MMP-9 inhibitor-I (0.2 μg) and TIMP-1 (0.1 μg) were
dissolved in 10% DMSO and saline, respectively. The
inhibitors and doses of MMP-9 were chosen based on
our previous studies [30]. The MMP-9 inhibitors were
intrathecally injected (0.2 μg in10 μl) 30 min before the
morphine injection. The MMP-9 and control siRNAs
were purchased from Dharmacon and the sequences of
these siRNAs were described in our previous study [30].
siRNA was dissolved in RNase-free water at the concen-
tration of 1 μg/μl as stock solution, and mixed with
polyethyleneimine (PEI, Fermentas), 10 min before
injection, to increase cell membrane penetration and
reduce the degradation [30,35]. PEI was dissolved in 5%
glucose, and 1 μg of siRNA was mixed with 0.18 μl of
PEI. siRNA (3 μg) was intrathecally injected 24 and 2 h
before the morphine injection. For intrathecal injection,
a lumbar puncture was made at L5-L6 level with a 30
gauge needle under a brief isoflurane anesthesia [62].
Behavioral test
Morphine analgesia was evaluated by tail-flick latencies
in hot water [63]. Briefly, tail-flick test was performed
by gently holding the mouse wrapped with a terry towel
and kept tail exposed. Then one third of the length of
the tail was immersed into the 52°C hot water, and the
response latency was recorded at the removal of the
whole tail from the water. A maximum cut-off value of
10 s was set to avoid thermal injury. To investigate
opioid-induced hyperalgesia, we also measured tail flick
latency at 48°C, as described in a recent study [64]. The
experimenters were blinded to the treatment or
genotype.
Immunohistochemistry
Two hours after morphine or vehicle (saline) injection,
animals were terminally anesthetized with isoflurane and
perfused through the ascending aorta with PBS followed
by 4% paraformaldehyde with 1.5% picric acid in 0.16 M
PB, and the DRGs (L4/L5) were removed and postfixed
in the same fixative overnight. DRG sections (12 μm)
were cut in a cryostat and processed for immunofluores-
cence. All the sections were blocked with 10% goat
serum, and incubated over night at 4°C with the primary
antibodies against MMP-9 (rabbit, 1:500-2000, Chemi-
con) and MOR (guinea pig, 1:1000, Chemicon), with 5%
goat serum. The sections were then incubated for 1 h at
room temperature with Cy3- or FITC- conjugated sec-
ondary antibody (1:400, Jackson Immunolab) with 1%
goat serum. For double immunofluorescence, sections
were incubated with a mixture of polyclonal and mono-
clonal primary antibodies followed by a mixture of
FITC- and CY3-congugated secondary antibodies [65].
The stained sections were examined under a Nikon
fluorescence microscopy, and images were captured
with a CCD camera (SPOT, Diagnostic Instruments).
All images were analyzed with NIH Image software or
Adobe Photoshop.
Western blot
Animals were terminally anesthetized with isoflurane at
1, 2, 3, and 24 h after morphine injection and transcar-
dially perfused with PBS. DRGs (L4/L5) and spinal cord
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dorsal horn segments (L4-L5) were rapidly removed and
homogenized in a lysis buffer containing a cocktail of
protease inhibitors and phosphatase inhibitors [66]. The
protein concentrations were determined by BCA Protein
Assay (Pierce). Thirty micrograms of proteins were
loaded into each lane and separated on SDS-PAGE gel
(4-15%, Bio-Rad). After the transfer, the blots were incu-
bated overnight at 4°C with polyclonal antibody against
MMP-9 (rabbit, 1:1000, Chemicon). For loading control,
the blots were probed with b-tubulin or GAPDH anti-
body (rabbit, 1:5000, Sigma).
Gelatin zymography
Because MMP-2 and MMP-9 are gelatinases, we used
gelatin zymography to determine the activity of MMP-9
and MMP-2 [28]. Animals were terminally anesthetized
with isoflurane at 0.5, 1, 2, and 3 h after morphine injec-
tion and transcardially perfused with PBS. DRGs (L4/L5)
were rapidly removed and homogenized in the same
lysis buffer as we used for Western blotting. Gelatin
zymography was conducted as previously described
[30,67]. Ten micrograms of proteins were loaded per
lane into the wells of precast gels (10% polyacrylamide
minigels containing 0.1% gelatin, Novex). After electro-
phoresis, each gel was incubated with 100 ml of devel-
opment buffer (50 mM Tris base, 40 mM HCl, 200 mM
NaCl, 5 mM CaCl2, and 0.2% Brij 35, Novex) at 37°C
for 14-18 h. Staining was performed with 100 ml of
0.5% Coomassie blue G-250 in 30% methanol and 10%
acetic acid for 1 h. Gelatinolytic activity was demon-
strated as clear zones or bands.
Primary DRG cultures and immunocytochemistry
DRGs were removed aseptically from 4-week old mice
and first incubated with collagenase (1.25 mg/ml,
Roche)/dispase-II (2.4 units/ml, Roche) at 37°C for 90
min, then digested with 0.25% trypsin (Cellgro) for 8
min at 37°C, followed by 0.25% trypsin inhibitor
(Sigma). Cells were then mechanically dissociated with a
flame polished Pasteur pipette in the presence of 0.05%
DNAse I (Sigma). Dissociated DRG neurons were cul-
tured in neurobasal defined medium with 2% B27 sup-
plement (Invitrogen) on coverslips precoated with poly-
D-lysine (100 μg/ml, Sigma) and laminin (10 μg/ml,
Invitrogen) at 36.5°C, with 5% carbon dioxide, in the
presence of 5 μM AraC to inhibit the proliferation of
non-neuronal cells,. To remove myelin debris and cell
clumps, a partial purification step was performed by
centrifugation through a BSA cushion (15%, Sigma).
DRG neurons were grown in cultures for 24 h before
use. DRG neurons were incubated with morphine (1, 10
and 50 μM), DAMGO (1 and 10 μM), and remifentanil
(1 and 10 μM), as well as morphine plus naloxone (10
and 50 μM), and morphine plus CTAP (D-Phe-Cys-Tyr-
D-Trp-Arg-Thr-Pen-Thr-NH2) (10 and 50 μM) for 2 h.
The concentrations of opioids were based on previous
studies in primary DRG cultures [39,40]. For immunocy-
tochemistry, DRG neurons were fixed with 4% parafor-
maldehyde for 20 min and incubated with MMP-9
(1:1000, rabbit, Chemicon) and NeuN (1:1000, mouse,
Millipore) overnight at 4°C. DAPI (4’,6-diamidino-2-phe-
nylindole, 1:5000, Invitrogen) was used to stain the cell
nucleus.
Quantitative real-time PCR
Mice were sacrificed after terminal anesthesia with iso-
flurane, and the L4-L5 DRGs were rapidly dissected.
Total RNA was extracted using RNeasy Plus Mini kit
(Qiagen). Quantity and quality of the eluted RNA sam-
ples were verified by NanoDrop spectrophotometer
(Thermo Fisher Scientific). A total of 0.5 μg of RNA
was reverse transcribed using Omniscript reverse tran-
scriptase according to the protocol of the manufacturer
(Qiagen). Specific primers for MMP-9 and TIMP-1 as
well as GAPDH control were designed using IDT Sci-
Tools Real-Time PCR software (Integrated DNA Tech-
nologies). The sequences of these primers were
described in Table 1. Quantitative PCR amplification
reactions contained the same amount of RT product:
7.5 μl of 2 × iQSYBR-green mix (BioRad) and 300 nM
of forward and reverse primers in a final volume of 15
μl. The thermal cycling conditions comprised 3 min
polymerase activation at 95°C, 45 cycles of 10 s dena-
turation at 95°C and 30 s annealing and extension at 60°
C, followed by a DNA melting curve for the determina-
tion of amplicon specificity. All experiments were per-
formed in duplicate. Primer efficiency was obtained
from the standard curve and integrated for calculation
of the relative gene expression, which was based on
real-time PCR threshold values of different transcripts
and groups [68,69].
In situ hybridization
Animals were transcardially perfused with PBS and 4%
paraformaldehyde after terminal anesthesia with isoflur-
ane. DRGs were collected and post-fixed overnight.
DRG tissues were sectioned at a thickness of 12 μm in a
cryostat and mounted on superfrost plus slides. MMP-9
riboprobes (0.47 kb) was generated by PCR. The reverse
primer contains T7 RNA polymerase binding sequence
(TGTAATACGACTCACTATAGGGCG) for the gen-
eration of the antisense riboprobe. DNA sequences were
transcribed in vitro with T7 RNA polymerase (Promega)
in the presence of digoxigenin-labeling mix. DRG sec-
tions were hybridized with MMP-9 riboprobe (1 μg/ml)
overnight at 65°C. After washing, sections were blocked
with 20% serum for 1 h at room temperature followed
by incubation with alkaline phosphatase-conjugated
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anti-digoxigenin antibody (1:2000; Roche Diagnostics)
overnight at 4°C. Sections were then incubated with a
mixture of nitro-blue tetrazolium (NBT) and 5-bromo-
4-chloro-3-indolyl-phosphate (BCIP) in alkaline phos-
phatase buffer for 24-48 h for color development. In situ
images were captured with a Nikon microscope under
bright-field.
Quantification
For cell counting in DRG sections, we randomly selected
4 sections from each DRG/animal and counted i) total
number of cells and ii) number of mRNA-positive (in
situ hybridization) or immunoreactive cells in these 4
sections and calculated the % of positive cells in DRG
sections, as we previously reported [1,65]. We included
4 animals per group for the quantification of histochem-
istry in DRG tissue sections. To quantify MMP-9 stain-
ing in cultured DRG neurons, we measured the intensity
of MMP-9-positive neurons as we previously reported
[41,70]. We included 4 cultures per condition and
examined all the cells in each culture. The total number
of cells in each culture condition varied from 399 to
746. Cell counting was conducted in a blinded manner.
For Western blotting and gelatin zymography, we mea-
sured the intensities of positive bands and included 4
animals per group for biochemical analyses. For beha-
vioral tests, we included n = 5-10 animals per group.
Statistical analysis
All the data are expressed by mean ± SEM. Differences
between groups were tested using ANOVA followed by
posthoc Bonferroni test and Student’s t-test. Some data
(n = 4 samples) were also tested by non-parametric
Kruskal-Wallis test and Mann-Whitney test, and the
same statistical results were obtained. The criterion for
statistical significance was P < 0.05.
Additional material
Additional file 1: Supplemental Figures.
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